Synopsis:- A pharma stock rose 4% after launching Pomalidomide Capsules in the U.S., a generic version of a cancer treatment drug. The product is available in 1mg–4mg strengths and targets a $3.2 billion market, while the company may benefit from 180 days of shared exclusivity.
The shares of the prominent pharmaceutical company gained up to 4.1 percent in today’s trading session after the company announces launch of Pomalidomide Capsules in the U.S. market.
With a market capitalization of Rs 17,122.90 crore, the shares of Natco Pharma Ltd were trading at Rs 954.90 per share, decreasing around 0.16 percent as compared to the previous closing price of Rs 956.40 apiece.
Product Launch
The shares of Natco Pharma Ltd have seen positive movement after, along with its partner Breckenridge Pharmaceutical, has launched Pomalidomide Capsules in the U.S., a generic version of Celgene’s Pomalyst®. The drug is mainly used to treat multiple myeloma patients who have already undergone at least two prior therapies. It is also indicated for AIDS-related Kaposi sarcoma and HIV-negative patients suffering from the same condition.
Furthermore, the capsules are available in 1mg, 2mg, 3mg, and 4mg strengths and are mainly distributed through specialty pharmacies and clinics in the U.S. market. According to industry data, the branded drug recorded around $3.2 billion in U.S. sales for the 12 months ending September 2025, while NATCO is expected to benefit from 180 days of shared exclusivity.
Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of NATCO Pharma Limited, said, “We are pleased to launch Pomalidomide Capsules in the U.S. This further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years.”
Financials
The company reported strong financial growth in Q3FY26, with revenue rising 36% from Rs 475 crore to Rs 647 crore, reflecting improved business momentum. However, profit growth was comparatively moderate, increasing 14% from Rs 132 crore to Rs 151 crore, indicating that while sales expanded significantly, margins saw only a gradual improvement during the period.
Between Dec 2024 and Dec 2025, the company’s operating performance showed volatility. Operating profit increased sharply from Rs 39 crore in Dec 2024 to Rs 548 crore in Mar 2025 and peaked at Rs 579 crore in Sep 2025, before declining to Rs 159 crore in Dec 2025. Similarly, OPM improved from 8% to 45%, then moderated to 25%.
Natco Pharma Ltd is an Indian pharmaceutical company focused on developing and manufacturing generic medicines and specialty drugs. Headquartered in Hyderabad, the company has a strong presence in oncology, cardiology, and antiviral therapies. It operates multiple manufacturing and research facilities and exports products to several global markets, including the United States.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma Stock Jumps 4% After Launching Pomalidomide Capsules in the US Market appeared first on Trade Brains.